To achieve optimal results, oncologists who treat multiple myeloma must be adept in individualizing patient management strategies, which includes stratifying patients based on risk and maximizing the depth and duration of treatment response. Oncologists also need to be aware of these approaches in the context of relapsed or refractory disease and the next generation of agents that may be useful for patients that become resistant to current regimens.|
This activity has been designed to meet the educational needs of hematologist-oncologists and medical oncologists involved in the care of patients with multiple myeloma.
At the conclusion of this activity, participants should be able to:
- Use cytogenetics, fluorescence in situ hybridization (FISH), and gene expression profiling to define patient prognosis and risk stratification
- Outline a treatment plan to achieve the desired response while balancing the risk for toxicities in high-risk and standard-risk myeloma patients
- Implement evidence-based strategies to prolong the duration of response in multiple myeloma patients
- Incorporate current consensus recommendations, guidelines, and the latest clinical evidence in the management of multiple myeloma
- Evaluate clinical data regarding the use of new agents in patients who develop resistance to or relapse from their initial therapy
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine, Curatio CME Institute, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Penn State College of Medicine and Curatio CME Institute adhere to ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and the program sponsors have a process in place to resolve any conflict of interest. Complete disclosure will be provided to program participants at the beginning of the activity. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
||Curatio CME Institute complies fully with the legal requirements of the Americans With Disabilities Act. If you are in need of special accommodation, please indicate your need in writing or contact Danielle Hesser-Watkins at (610) 423-4697 or via
e-mail at firstname.lastname@example.org.